Miller 2011.

Methods	This was a 2‐arm, parallel group RCT The RCT phase lasted 12 weeks, followed by a 12‐week observational follow‐up phase with no treatment
Participants	The trial included 21 participants with moderate to severe HS, defined as Hurley stage II or III, for at least 6 months
Interventions	2 groups randomised in a 1:2 ratio (placebo:active): s/c placebo ‐ 6 participants, of whom 1 dropped out during the RCT phase s/c adalimumab, initial dose 80 mg, then 40 mg every other week for 12 weeks ‐ 15 participants, of whom 1 dropped out during the RCT phase
Outcomes	Primary outcomes Unmodified Sartorius severity scale score at week 12 (week 24 used to assess recurrence) Hurley score at week 12 (week 24 for recurrence) Secondary outcomes Pain VAS score at week 12 (week 24 for recurrence) Number of self‐reported days with lesions between visits DLQI at week 12 (week 24 for recurrence) Manchester (postinflammatory) Scar Score at week 24 Physician Global Assessment scar score at week 24
Notes	The study did not reach its recruitment target of 30 participants because the study medication exceeded its expiry date Abbott, manufacturers of adalimumab, provided the active drug, placebo, and computer randomisation. No salary was paid to the investigators or to the department performing the study
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The random sequence generation was computer generated
Allocation concealment (selection bias)	Unclear risk	Sequentially numbered containers were used, but the paper did not specify if the containers were opaque
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical syringes were used as well as the same dosing schedule. The adverse effects were unlikely to have caused unblinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Treating clinicians assessed the outcomes but were unlikely to be unblinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial undertook ITT analysis with LOCF and first observation carried backwards. The authors stated: "The combination of last observation carried forward and first observation carried backward ensures that for a given patient both missing values after the last observation as well as missing values prior to the first observation are imputed"
Selective reporting (reporting bias)	Unclear risk	EudraCT: 2006‐005297‐48, but a search for the study was unsuccessful
Other bias	High risk	Baseline disease severity was higher in the adalimumab group